Table 2.
Comparison between peripheral blood immune cell profiles in CRC patients and healthy donors
| Healthy controls (N = 19) | CRC patients (N = 71) | |||||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | P value | Corrected P* value | |
| Subset distribution | ||||||
| T cells (%)* | 59.4 | 8.2 | 57.5 | 13.2 | 0.669T | 0.883 |
| CD8+ T cells (%)* | 20.7 | 8.3 | 18.7 | 10.4 | 0.378U | 0.670 |
| CD4+ T cells (%)* | 42.1 | 6.1 | 44.3 | 12.2 | 0.400T | 0.689 |
| CD127lowCD25+ Treg (%)* | 5.5 | 0.5 | 7.7 | 2.4 | 0.000U | 0.000 |
| NK cells (%) | 12.8 | 5.4 | 15.4 | 8.5 | 0.508U | 0.768 |
| CD56dim NK cells (%) | 93.4 | 4.2 | 95 | 4.2 | 0.054U | 0.197 |
| CD56bright NK cells (%) | 6.6 | 4.2 | 5.1 | 4.2 | 0.057U | 0.196 |
| NKT-like cells (%) | 4.3 | 2.8 | 6.1 | 6.4 | 0.656U | 0.904 |
| CD56dim NK cells | ||||||
| CD16 + (%) | 85.3 | 6.1 | 83.7 | 10.2 | 0.909U | 0.989 |
| CD158a + (%) | 35.2 | 17.1 | 31.9 | 16.9 | 0.477U | 0.739 |
| CD158b + (%) | 37 | 11.4 | 37.5 | 14.7 | 0.786U | 0.937 |
| NKG2A + (%) | 45.6 | 19.3 | 43.4 | 19 | 0.656T | 0.884 |
| NKG2A + (MFI) | 6398 | 2138 | 7368 | 2459 | 0.275U | 0.533 |
| NKG2C + (%) | 13.7 | 13 | 16.2 | 17.9 | 0.909U | 0.972 |
| NKG2C + (MFI) | 2506 | 2797 | 2965 | 3094 | 0.213U | 0.440 |
| CD161 (MFI) | 3111 | 804 | 3057 | 1130 | 0.816T | 0.903 |
| CD8 + (%) | 34.3 | 14.3 | 31.5 | 14.4 | 0.467U | 0.742 |
| CD8 + (MFI) | 3481 | 774 | 3067 | 1159 | 0.067U | 0.208 |
| DNAM-1 (MFI) | 560 | 106 | 548 | 146 | 0.741T | 0.919 |
| NKG2D + (%) | 89.9 | 4.4 | 91.4 | 4.9 | 0.134U | 0.346 |
| NKG2D + (MFI) | 3600 | 1108 | 3429 | 1113 | 0.554T | 0.818 |
| NKp30 (MFI) | 1960 | 752 | 1630 | 900 | 0.052U | 0.202 |
| NKp44 + (%) | 0.7 | 0.6 | 0.6 | 0.6 | 0.081U | 0.239 |
| NKp44 (MFI) | 131 | 13 | 115 | 26 | 0.002U | 0.041 |
| NKp46 + (%) | 48.7 | 18 | 34.7 | 16.9 | 0.002T | 0.031 |
| NKp46 (MFI) | 732 | 345 | 478 | 271 | 0.003U | 0.031 |
| CD56bright NK cells | ||||||
| CD16 + (%) | 3 | 2.8 | 2.5 | 1.8 | 0.415U | 0.695 |
| CD158a + (%) | 6.6 | 4.2 | 7 | 4.8 | 0.793U | 0.928 |
| CD158b + (%) | 6.4 | 3 | 8.6 | 5.5 | 0.097U | 0.273 |
| NKG2A + (%) | 6.6 | 4.6 | 4.5 | 3.3 | 0.044U | 0.210 |
| NKG2A + (MFI) | 17,020 | 7986 | 19,052 | 5829 | 0.165 U | 0.365 |
| NKG2C + (%) | 1.9 | 2.2 | 1.2 | 1.1 | 0.145U | 0.333 |
| NKG2C + (MFI) | 1760 | 967 | 3038 | 3831 | 0.017U | 0.105 |
| CD161 (MFI) | 2128 | 568 | 1767 | 578 | 0.012U | 0.093 |
| CD8 + (%) | 2.4 | 1.6 | 1.8 | 1.7 | 0.044U | 0.195 |
| CD8 + (MFI) | 2951 | 886 | 3098 | 1318 | 0.945U | 0.977 |
| DNAM-1 (MFI) | 765 | 130 | 782 | 161 | 0.675T | 0.872 |
| NKG2D + (%) | 6.2 | 4.1 | 4.7 | 3.7 | 0.062U | 0.202 |
| NKG2D + (MFI) | 5321 | 1354 | 6210 | 1837 | 0.037U | 0.191 |
| NKp30 (MFI) | 2145 | 418 | 2413 | 769 | 0.048T | 0.198 |
| NKp44 + (%) | 2 | 1.5 | 1.3 | 1.2 | 0.024U | 0.135 |
| NKp44 (MFI) | 252 | 49 | 236 | 78 | 0.099U | 0.267 |
| NKp46 + (%) | 86.1 | 8.1 | 80.7 | 14.3 | 0.135U | 0.322 |
| NKp46 (MFI) | 2343 | 613 | 2090 | 812 | 0.211T | 0.451 |
| NKT-like cells | ||||||
| CD16 + (%) | 35.6 | 17.6 | 24.6 | 13.7 | 0.013U | 0.090 |
| CD158a + (%) | 12 | 12.9 | 9.4 | 9.8 | 0.957U | 0.973 |
| CD158b + (%) | 18.8 | 19.2 | 19.2 | 19.2 | 0.793U | 0.910 |
| NKG2A + (%) | 31.9 | 25.4 | 28.3 | 21 | 0.692U | 0.876 |
| NKG2A + (MFI) | 4529 | 4416 | 3444 | 3757 | 0.604U | 0.851 |
| NKG2C + (%) | 15 | 15.6 | 14.2 | 13.3 | 0.909U | 0.955 |
| NKG2C + (MFI) | 2308 | 2256 | 3205 | 3300 | 0.283U | 0.532 |
| CD161 (MFI) | 4509 | 4407 | 4445 | 5434 | 0.452U | 0.737 |
| CD8 + (%) | 64.1 | 16.9 | 70.4 | 17.9 | 0.134U | 0.332 |
| CD8 + (MFI) | 11,870 | 6011 | 11,673 | 5556 | 0.968U | 0.968 |
| DNAM-1 (MFI) | 847 | 211 | 766 | 279 | 0.238T | 0.476 |
| NKG2D + (%) | 85.4 | 14.5 | 88.6 | 10.7 | 0.345U | 0.629 |
| NKG2D + (MFI) | 4730 | 1589 | 4995 | 2041 | 0.602T | 0.868 |
| NKp30 (MFI) | 217 | 70.1 | 250 | 136 | 0.797U | 0.898 |
| NKp44 + (%) | 1.4 | 1 | 1.4 | 1.2 | 0.774U | 0.941 |
| NKp44 (MFI) | 134 | 17 | 120 | 33 | 0.002U | 0.025 |
| NKp46 + (%) | 5.4 | 1.9 | 4.6 | 2.8 | 0.011U | 0.097 |
| NKp46 (MFI) | 112 | 53 | 61 | 47 | 0.000U | 0.000 |
The distribution of circulating immune cell subsets and their immunophenotype was compared between CRC patients (N = 71) and healthy donors (N = 19). P values were corrected for multiple testing using the Benjamini–Hochberg method, by which adjusted P values were calculated (indicated by P*). P* values ≤ 0.05 were considered statistically significant and are indicated in bold
*T cells were investigated in 10 healthy donors and 47 CRC patients
TIndependent samples T test
UMann-Whitney U test